Short-term BMI-SDS change during child and adolescent psychiatric hospitalization: associations with antipsychotic treatment and length of stay
- 1Faculty of Medicine, University of Ljubljana , ,
- 2Department for Child Psychiatry, University Children’s Hospital Ljubljana, University Medical Centre Ljubljana , ,
Abstract
Children and adolescents receiving inpatient psychiatric treatment may be at increased risk of short-term weight gain-related changes, particularly during antipsychotic exposure. In this retrospective cohort study we analyzed a patient-level cohort of 776 unique patients younger than 18 years treated between 2022 and 2024, after exclusion of eating disorder diagnoses and repeated hospitalizations. Clinical data were extracted from electronic medical records and included demographic and clinical characteristics, antipsychotic treatment, and anthropometric measurements. The median hospitalization duration was 3.0 days (IQR 2.0-7.0). Repeated BMI-SDS measurements permitting calculation of BMI-SDS change were available for 228 patients. Mean BMI-SDS change was +0.071 (SD = 0.242). BMI-SDS increased significantly among patients exposed to antipsychotics (n = 152; mean change +0.107, p < 0.001), whereas no significant change was observed among patients without antipsychotic exposure (n = 76). BMI-SDS change differed across antipsychotic treatment groups (Kruskal-Wallis p = 0.0006; ϵ² = 0.081). However, olanzapine monotherapy was not significantly different from no antipsychotic treatment after correction for multiple comparisons, although exploratory analysis showed a higher risk of BMI-SDS increase ≥0.5 with olanzapine exposure (NNH = 3.7, 95% CI 2.2–10.2). In multivariable linear regression analysis, longer hospitalization (B = 0.0035 per day, 95% CI 0.002-0.005, p < 0.001) and any antipsychotic exposure (B = 0.0668, 95% CI 0.003-0.131, p = 0.042) were associated with higher follow-up BMI-SDS after adjustment for baseline BMI-SDS. Sex, age and F20-F29 diagnosis were not significantly associated with follow-up BMI-SDS. These findings suggest that short-term BMI-SDS change during child and adolescent psychiatric hospitalization is associated with antipsychotic treatment and length of hospitalization. The results do not support a significant olanzapine dose-response relationship and should be interpreted as anthropometric associations rather than evidence of metabolic dysfunction or causality.
Related
- Associations of Cancer Rehabilitation During Hospitalization for Cancer Treatment With Survival and Post–Discharge Healthcare Utilization: A Multicenter Retrospective Cohort Study
- ADHD Presentations and Severity in Adults: Psychometric Profiles, Psychiatric Comorbidities, and Emotional Dysregulation in Relation to Psychiatric Hospitalization
- Associations of Depressive Symptoms With COVID-19 Hospitalization or Death: The C4R Study
- Pre-treatment EEG microstates and response to antipsychotic drugs in first episode psychosis
- Prenatal cannabis use disorder and postpartum psychiatric emergency department visits: A retrospective cohort study of trends and associations in California, 2016–2021
BibTeX
@article{svigelj2026shortterm,
title = {{Short-term BMI-SDS change during child and adolescent psychiatric hospitalization: associations with antipsychotic treatment and length of stay}},
author = {Marjetka Švigelj and Maja Drobnič Radobuljac and Barbara Plemeniti Tololeski and Anja Turin and Primož Kotnik},
journal = {Frontiers in psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1942502},
url = {https://europepmc.org/article/PMC/PMC13672501},
note = {CC BY},
}
RIS
TY - JOUR
TI - Short-term BMI-SDS change during child and adolescent psychiatric hospitalization: associations with antipsychotic treatment and length of stay
AU - Marjetka Švigelj
AU - Maja Drobnič Radobuljac
AU - Barbara Plemeniti Tololeski
AU - Anja Turin
AU - Primož Kotnik
PY - 2026
DA - 2026/10/02
JO - Frontiers in psychiatry
DO - 10.3389/fpsyt.2026.1942502
UR - https://europepmc.org/article/PMC/PMC13672501
AB - Children and adolescents receiving inpatient psychiatric treatment may be at increased risk of short-term weight gain-related changes, particularly during antipsychotic exposure. In this retrospective cohort study we analyzed a patient-level cohort of 776 unique patients younger than 18 years treated between 2022 and 2024, after exclusion of eating disorder diagnoses and repeated hospitalizations. Clinical data were extracted from electronic medical records and included demographic and clinical characteristics, antipsychotic treatment, and anthropometric measurements. The median hospitalization duration was 3.0 days (IQR 2.0-7.0). Repeated BMI-SDS measurements permitting calculation of BMI-SDS change were available for 228 patients. Mean BMI-SDS change was +0.071 (SD = 0.242). BMI-SDS increased significantly among patients exposed to antipsychotics (n = 152; mean change +0.107, p < 0.001), whereas no significant change was observed among patients without antipsychotic exposure (n = 76). BMI-SDS change differed across antipsychotic treatment groups (Kruskal-Wallis p = 0.0006; ϵ² = 0.081). However, olanzapine monotherapy was not significantly different from no antipsychotic treatment after correction for multiple comparisons, although exploratory analysis showed a higher risk of BMI-SDS increase ≥0.5 with olanzapine exposure (NNH = 3.7, 95% CI 2.2–10.2). In multivariable linear regression analysis, longer hospitalization (B = 0.0035 per day, 95% CI 0.002-0.005, p < 0.001) and any antipsychotic exposure (B = 0.0668, 95% CI 0.003-0.131, p = 0.042) were associated with higher follow-up BMI-SDS after adjustment for baseline BMI-SDS. Sex, age and F20-F29 diagnosis were not significantly associated with follow-up BMI-SDS. These findings suggest that short-term BMI-SDS change during child and adolescent psychiatric hospitalization is associated with antipsychotic treatment and length of hospitalization. The results do not support a significant olanzapine dose-response relationship and should be interpreted as anthropometric associations rather than evidence of metabolic dysfunction or causality.
SN - 1664-0640
ER -